(ALNY) Alnylam Pharmaceuticals, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ALNY) Alnylam Pharmaceuticals, Inc. Complete Analysis Pack
Alnylam's Business Model Canvas: RNAi Innovation, Partnerships, Growth
Unlock the full strategic blueprint behind Alnylam Pharmaceuticals, Inc.'s business model. This concise Business Model Canvas reveals how the company creates value through RNAi innovation, key partnerships, and a focused commercial strategy. Ideal for investors, analysts, and strategists who want a clear edge—get the full version to see every building block.
Partnerships
Regeneron RNAi collaboration
Regeneron Pharmaceuticals is Alnylam Pharmaceuticals, Inc.’s research partner for RNAi in ocular and CNS targets, helping extend RNAi beyond the liver into harder-to-drug tissues. In 2025, Alnylam reported $2.3 billion in total net product revenues, while this collaboration kept the pipeline focused on high-value, technically difficult targets.
Sanofi Genzyme alliance
Sanofi Genzyme adds global rare-disease reach to Alnylam Pharmaceuticals, Inc. By 2025, Alnylam had 4 approved RNAi medicines, and the alliance helps move selected programs from development into wider markets with stronger commercialization scale.
This partnership matters because rare-disease launches are small at first but global execution is hard; Sanofi Genzyme helps extend that footprint and support broader RNAi growth.
Novartis licensing agreement
Novartis AG adds a large-pharma backer to Alnylam Pharmaceuticals, Inc.'s RNAi platform; Novartis reported $50.3 billion in net sales in 2024, so the deal gives Alnylam external development reach and a path to share in future commercial upside. It also acts as third-party validation that Alnylam's RNAi science can attract blue-chip licensing partners.
Vir Biotechnology collaboration
Vir Biotechnology is part of Alnylam Pharmaceuticals, Inc.'s external partnership network, and it supports antiviral R&D while widening disease-area optionality beyond RNAi core programs. Alnylam had 4 approved medicines and, in FY2025, kept scaling its broader pipeline from this partner-led model.
- Supports antiviral research.
- Extends disease-area reach.
- Reduces single-platform dependence.
Dicerna Ionis PeptiDream deals
Alnylam’s partnerships with Dicerna, Ionis, and PeptiDream expand target access, discovery, and tech sharing, which lowers early-stage R&D risk and keeps the RNAi pipeline fed. In FY2024, Alnylam reported $2.25 billion in product revenue, so these alliances help extend growth without relying only on internal discovery.
- Broader target access
- Shared discovery tools
- Lower R&D burden
- Supports pipeline growth
Alnylam’s Partner-Powered RNAi Engine Drives $2.3B in FY2025 Sales
Alnylam Pharmaceuticals, Inc. relies on a partner-heavy model: Regeneron Pharmaceuticals for hard-to-reach RNAi targets, Sanofi Genzyme for rare-disease scale, Novartis AG for external validation, and Vir Biotechnology plus other discovery partners to widen the pipeline. In FY2025, Alnylam reported $2.3 billion in net product revenues and 4 approved RNAi medicines.
| Partner | Role |
|---|---|
| Regeneron Pharmaceuticals | Ocular and CNS RNAi |
| Sanofi Genzyme | Rare-disease commercialization |
| Novartis AG | Licensing validation |
What is included in the product
Detailed Word Document
A concise Business Model Canvas summary of Alnylam’s RNAi drug platform, partnerships, and commercial strategy.
Customizable Excel Spreadsheet
Quickly maps Alnylam’s RNAi business model in one clear snapshot.
Reference Sources
Gives a credible source trail for Alnylam Pharmaceuticals, Inc. that supports faster due diligence and more confident decisions.
Activities
RNAi target discovery
Alnylam starts with RNAi target discovery by finding disease-causing genes and designing siRNA molecules to silence them; target validation and chemistry optimization are the core work. As of FY2025, this engine had already produced 4 marketed medicines, showing how one discovery step feeds the whole pipeline.
Clinical development
Alnylam Pharmaceuticals, Inc. runs preclinical and clinical studies across rare and prevalent diseases, from inherited genetic disorders to cardio-metabolic, hepatic, CNS, and ocular programs. Its clinical engine turns RNAi targets into approvals, building on 4 approved medicines and a pipeline that keeps moving from discovery to market.
Regulatory approvals
Alnylam’s regulatory approvals work drives global filings, label updates, safety changes, and new-indication submissions, which keep approved RNAi drugs growing after launch. In 2024, Alnylam reported about $2.2 billion in product revenue, showing how post-approval life-cycle work supports a scaled franchise.
Manufacturing and quality control
Alnylam Pharmaceuticals, Inc. keeps CMC work tight for its siRNA drugs, with strict manufacturing and quality control to protect batch consistency and supply reliability. That matters because oligonucleotide drugs need exact control at every step, and Alnylam had 4 approved medicines in 2025, so the same system must support both commercial launch supply and clinical trial material.
- Controls siRNA CMC process
- Enforces batch consistency
- Supports launch and trial supply
- Backs 4 approved medicines
Commercialization and medical affairs
Alnylam’s commercialization and medical affairs team drives ONPATTRO, GIVLAARI, and OXLUMO in approved markets, turning a 3-product rare-disease franchise into revenue. Medical teams educate specialists and support access, while commercial execution helps convert pipeline assets into sales across the U.S., Europe, and other approved regions.
- 3 approved medicines: ONPATTRO, GIVLAARI, OXLUMO
- Focus: specialist education and patient access
Alnylam’s RNAi Engine Powers 4 Drugs and $2.2B in Revenue
Alnylam Pharmaceuticals, Inc. focuses on RNAi target discovery, preclinical and clinical development, and global regulatory work that turns siRNA programs into approved drugs. In FY2025, it had 4 marketed medicines and reported about $2.2 billion in product revenue in FY2024.
| Key activity | FY2025 / FY2024 data |
|---|---|
| Marketed medicines | 4 |
| Product revenue | about $2.2 billion |
Full Document Unlocks After Purchase
Business Model Canvas
This Alnylam Pharmaceuticals, Inc. Business Model Canvas preview is not a sample—it’s a live view of the exact document you’ll receive after purchase. The final file includes the same content, formatting, and structure shown here, with no hidden changes or filler. Once you buy, you’ll download this same ready-to-use document in its complete form.
Resources
RNAi platform
Alnylam’s key resource is its RNAi platform, which silences disease genes at the mRNA level and drives its pipeline and marketed drugs. In 2024, the company reported $2.2 billion in net product revenue, showing how this platform has moved from science to scale.
Approved therapies
Alnylam Pharmaceuticals, Inc.’s approved therapies, ONPATTRO, GIVLAARI, and OXLUMO, anchor its commercial base and brand recognition. In 2024, Alnylam reported total revenue of $1.65 billion, with product sales funding continued R&D and pipeline expansion.
Pipeline assets
Alnylam Pharmaceuticals, Inc. pipeline assets span 10 programs, including givosiran, cemdisiran, ALN-AAT02, ALN-HBV02, zilebesiran, ALN-HSD, fitusiran, inclisiran, lumasiran expansion, and vutrisiran. They cover rare disease, cardiometabolic, liver, and hematology areas, and are the main engine for future growth beyond the company’s 2025 revenue base.
Intellectual property
Alnylam Pharmaceuticals, Inc. relies on patents, licensing rights, and proprietary chemistry to defend its RNAi inventions. In biotech, IP is the moat: drug development can take 10+ years and cost over $1 billion, so exclusive rights help protect pricing power and boost partnering value.
- Patents protect core RNAi assets.
- Licenses widen market reach.
- IP supports exclusivity and deals.
That legal barrier is central to Alnylam Pharmaceuticals, Inc.’s long-term value.
Scientific talent and Cambridge HQ
Alnylam Pharmaceuticals, Inc. is based in Cambridge, Massachusetts, and its scientific talent is a core asset in a research-led RNAi model. In 2025, the company reported 2,100+ employees, with most value created by teams that move programs from discovery to development and commercialization.
- Cambridge HQ anchors science talent.
- Human capital drives pipeline execution.
- Research-heavy model depends on expertise.
Alnylam’s RNAi engine is scaling into a $2.2B revenue business
Alnylam Pharmaceuticals, Inc.’s core resources are its RNAi platform, 4 marketed drugs, and deep IP. In 2025, the company had 2,100+ employees, and its 2024 product revenue of $2.2 billion showed how those resources now support scale.
| Resource | 2025/2024 data |
|---|---|
| RNAi platform | Core engine |
| Marketed drugs | 4 |
| Employees | 2,100+ |
| Product revenue | $2.2 billion |
Value Propositions
First-in-class RNAi medicines
Alnylam Pharmaceuticals, Inc. sells first-in-class RNAi medicines that silence disease-causing genes, not just symptoms, which sets its platform apart in biopharma. As of 2025, it had 4 marketed RNAi therapies, showing the value of a validated mechanism with real commercial reach.
Root-cause treatment approach
Alnylam Pharmaceuticals targets the genetic root cause of disease with RNAi, which matters most in rare inherited disorders where symptom-only care falls short. In 2025, the Company reported about $2.6 billion in product revenue, showing demand for its disease-modifying drugs like Amvuttra and Oxlumo.
Approved rare-disease options
Alnylam Pharmaceuticals, Inc. markets three approved rare-disease drugs: Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, and Oxlumo for primary hyperoxaluria type 1. These target severe, underserved conditions, including PH1, which affects about 1 to 3 people per million, creating immediate clinical need and durable commercial value.
Broad therapeutic reach
Alnylam Pharmaceuticals, Inc. spreads its RNAi pipeline across genetic, cardio-metabolic, hepatic, CNS, and ocular diseases, so one weak franchise does not drive the whole story. With 4 marketed therapies already in hand, that breadth supports several long-run shots at scale across rare and larger markets.
- 5 disease areas
- 4 approved therapies
- Lower single-franchise risk
- More long-term market options
Potential durable dosing
Alnylam Pharmaceuticals, Inc. builds value on RNAi medicines that can last for weeks to months after dosing, so chronic care can move away from daily pills. In 2025, AMVUTTRA was given every 3 months after loading doses for hATTR amyloidosis and, by Q2 2025, Alnylam reported $1.2 billion in total revenue, showing demand for lower-burden treatment.
- Longer effect can mean fewer doses
- Less frequent use can lift adherence
- Quarterly dosing fits chronic therapy
Alnylam’s RNAi drugs are turning root-cause science into real sales
Alnylam Pharmaceuticals, Inc. creates value with RNAi drugs that silence disease-driving genes, not just symptoms, and that has turned into real sales: 2025 product revenue was about $2.6 billion. Its approved rare-disease medicines, led by AMVUTTRA, offer durable dosing with quarterly maintenance, which can improve adherence and lower treatment burden.
| Value proposition | 2025 data |
|---|---|
| RNAi root-cause therapy | 4 marketed therapies |
| Commercial traction | About $2.6 billion revenue |
| Lower dosing burden | AMVUTTRA quarterly |
Customer Relationships
Specialist physician engagement
Alnylam’s rare-disease drugs depend on specialist diagnosis, so it works closely with neurologists, hepatologists, nephrologists, and other expert prescribers. With 4 approved medicines in its 2025 portfolio, education is a core relationship tool because many rare diseases affect only a small patient pool and need fast, accurate referral and treatment.
Patient support services
Alnylam Pharmaceuticals, Inc. ties patient support to access and reimbursement help because rare-disease therapy is hard to start and keep on board; rare diseases affect about 1 in 10 people worldwide. In 2025, Alnylam reported about $2.5 billion in net product revenues, so keeping patients through coverage and logistics barriers matters directly to sales.
Medical science liaison support
Alnylam Pharmaceuticals, Inc. uses field medical teams to share clinical data with healthcare professionals, support scientific exchange, and engage investigators across its 4 approved RNAi medicines. In high-complexity specialty care, that medical science liaison support helps answer treatment questions fast and keeps trial and real-world evidence flowing.
Long-term treatment follow-up
Alnylam Pharmaceuticals, Inc. builds long-term treatment follow-up into its Customer Relationships because its 4 approved RNAi medicines are often used chronically, with ongoing checks for safety, adherence, and outcomes. That steady contact helps keep patients on therapy and also expands real-world evidence from repeated monitoring.
- 4 chronic therapies need regular follow-up
- Monitoring supports safety and adherence
- Longer use improves real-world evidence
Payer and access management
For Alnylam Pharmaceuticals, Inc., payer and access management is a core relationship because its rare-disease RNAi drugs face reimbursement reviews that can decide uptake. In 2025, the company kept working with payers, health systems, and specialty pharmacies to secure coverage and prior authorization for therapies with high annual costs, so access speed directly shapes patient starts.
- Coverage drives first-patient uptake.
- Prior auth can slow starts.
- Access wins support revenue growth.
Alnylam’s 2025 Growth Runs Through Specialists, Payers, and Pharmacies
Alnylam Pharmaceuticals, Inc. keeps close ties with specialists, payers, and specialty pharmacies because rare-disease RNAi drugs need fast diagnosis, prior authorization, and long follow-up. In 2025, 4 approved medicines drove about $2.5 billion in net product revenues, so access support and adherence work directly protect sales.
| Customer relationship | 2025 data |
|---|---|
| Approved medicines | 4 |
| Net product revenues | $2.5 billion |
| Focus | Specialists, payers, pharmacies |
Channels
Specialty physician prescribing
Specialty physician prescribing is Alnylam Pharmaceuticals, Inc.'s main patient channel: rare-disease care often starts in expert centers, where the company’s 4 marketed RNAi therapies are diagnosed and initiated by specialists. In 2025, this channel stayed critical as Alnylam kept expanding prescriber education to support its $2.2 billion 2024 product revenue base and drive use in small, high-complexity patient groups.
Specialty pharmacy distribution
Alnylam Pharmaceuticals, Inc. uses limited specialty pharmacy networks for rare-disease drugs like Amvuttra and Oxlumo, which helps manage prior authorizations, cold-chain delivery, and refill follow-up. This model supports adherence and safety oversight, and it is standard for high-touch medicines with small patient pools.
Specialty pharmacies also reduce dispensing errors and keep therapy monitoring close, which matters when treatment is long term and costly.
Hospital and clinic administration
Hospital and clinic administration is key for Alnylam Pharmaceuticals, Inc. because specialty therapies are often started and watched in infusion centers and hospital sites, where diagnosis, lab checks, and adverse-event monitoring happen. This channel also supports access to rare-disease patients through specialist prescribers and prior-authorization workflows, which can speed treatment start.
Payer and formulary access
Health plans and integrated delivery systems shape Alnylam Pharmaceuticals, Inc.'s reach because payer access decides whether patients get covered therapy. With 4 marketed medicines, formulary placement and prior-authorization rules can make or break uptake, so access teams are a core commercial channel.
- Health plans drive adoption.
- Formulary status expands patient reach.
- Access teams secure coverage.
Partner commercialization networks
Partner commercialization networks let Alnylam use strategic allies to reach markets it does not cover directly, especially in selected programs and geographies. In 2025, this model helped support commercialization beyond its own footprint while Alnylam still drove core sales from its own channels.
- Extends reach in selected programs
- Supports sales outside direct footprint
- Broadens channel coverage with partners
How Alnylam Reaches Patients: Specialists, Specialty Pharmacies, and Payers
Alnylam Pharmaceuticals, Inc. reaches patients mainly through specialist prescribers, specialty pharmacies, and hospital/clinic sites, since rare-disease starts happen in expert centers and need tight monitoring. Its 4 marketed RNAi therapies depend on payer approval and access-team support, because coverage and prior authorization decide uptake.
| Channel | Role | Data |
|---|---|---|
| Specialist prescribers | Diagnosis and start | 4 marketed therapies |
| Specialty pharmacies | Dispense and refill | High-touch rare-disease model |
| Payers | Coverage gate | Formulary and PA drive access |
Customer Segments
hATTR amyloidosis patients
Adults with hereditary transthyretin-mediated amyloidosis are a core customer segment for Alnylam Pharmaceuticals, Inc.; the disease is rare, progressive, and usually managed by specialty centers. ONPATTRO and related RNAi programs are built for this group, with global disease estimates often cited at about 50,000 people.
Acute hepatic porphyria patients
Adults with acute hepatic porphyria are a rare group, with prevalence around 1 in 100,000, and the disease can trigger severe neurovisceral attacks that often need specialist care. Alnylam Pharmaceuticals, Inc.'s GIVLAARI serves this segment in specialist centers, where even 1 treated patient can matter because the condition is debilitating and the addressable pool is very small.
Primary hyperoxaluria type 1 patients
Primary hyperoxaluria type 1 is an ultra-rare, high-unmet-need genetic kidney disease, and Alnylam Pharmaceuticals, Inc. targets these patients with OXLUMO. Estimates put PH1 prevalence at roughly 1 to 3 per million people, and diagnosis plus long-term care usually run through specialist metabolic and nephrology centers.
Future pipeline disease groups
Alnylam Pharmaceuticals, Inc.'s future pipeline targets patient groups in ATTR cardiomyopathy, hemophilia, HBV, hypertension, NASH, complement-mediated disorders, and AAT deficiency liver disease. That widens its addressable market across diseases that affect millions, including HBV at about 254 million people worldwide and ATTR-CM at more than 300,000 in the U.S.
- ATTR-CM and hemophilia expand rare-disease reach
- HBV and NASH add large chronic-disease pools
- Complement and AATD create new specialty segments
Specialty providers and payers
Specialty providers and payers are the gatekeepers for Alnylam Pharmaceuticals, Inc.: physicians and hospital specialists confirm the rare-disease diagnosis, then health plans decide access and reimbursement. In 2025, that makes institutional buy-in as important as clinical efficacy, because a therapy can only scale when the site of care and payer pathway both open.
- Physicians drive diagnosis.
- Hospitals deliver specialty care.
- Payers control access and reimbursement.
Alnylam’s Rare-Disease Base Is Small, but Its Pipeline Targets Bigger Markets
Alnylam Pharmaceuticals, Inc. serves a small but high-value base of rare-disease patients in specialty care, led by hereditary transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria type 1. Its pipeline broadens the reach into larger chronic pools like HBV and ATTR-CM, while payers and specialist physicians control access.
| Segment | Scale | Gatekeeper |
|---|---|---|
| hATTR, AHP, PH1 | Ultra-rare | Specialists |
| ATTR-CM, HBV | Large | Payers |
Cost Structure
Research and discovery spending
Alnylam Pharmaceuticals, Inc. keeps research and discovery as a core fixed cost: target identification and siRNA design are central to its RNAi platform. In the latest reported FY2024 results, research and development expense was about $1.3 billion, roughly half of revenue, showing how much spend sits upstream of commercialization.
Clinical trial expenditure
Late-stage clinical trial expenditure is one of Alnylam Pharmaceuticals, Inc.’s biggest cost lines, because each indication needs sites, investigators, monitoring, and data management. Industry estimates put Phase 3 programs at roughly $50 million to $100 million-plus per trial, and Alnylam’s 2025 R&D spend remained above $1 billion, showing how fast multi-indication development burns cash.
Manufacturing and CMC costs
Alnylam Pharmaceuticals, Inc. runs a costly oligonucleotide CMC chain: GMP synthesis, purification, analytics, and tight batch release controls all add expense. As products move from launch to scale, supply assurance and redundancy keep per-unit costs high, so manufacturing spend rises with commercialization.
Sales and medical affairs
Alnylam Pharmaceuticals, Inc.'s rare-disease launches depend on field teams, nurse education, and payer access help, so sales and medical affairs are service-heavy and keep SG&A large. This model fits its 2025 commercial buildout: more support per patient, more touchpoints, and higher selling costs than a standard drug launch.
- Field teams drive launch adoption.
- Medical affairs train and support HCPs.
- Access support is critical for coverage.
- SG&A stays material in rare disease.
Partnership and regulatory obligations
Alnylam Pharmaceuticals, Inc. carries milestone and royalty duties that move with partnered programs, while regulatory work and pharmacovigilance keep adding fixed operating cost. In FY2024, revenue was about $2.2B, showing that these obligations sit inside a large, active operating model.
- Milestones and royalties hit partner deals.
- Safety monitoring adds ongoing expense.
- Regulatory filings need steady spend.
Alnylam’s Heavy R&D Spend Keeps Costs Elevated
Alnylam Pharmaceuticals, Inc. runs a cost-heavy model: R&D stays above $1 billion, CMC and trial work keep fixed spend high, and SG&A rises with rare-disease launches. Partner milestones, royalties, and safety monitoring add recurring operating cost.
| Cost line | Latest data |
|---|---|
| R&D | Above $1.0B in FY2025 |
| Revenue | About $2.2B in FY2024 |
Revenue Streams
Product sales ONPATTRO
ONPATTRO is one of Alnylam Pharmaceuticals, Inc.’s 4 marketed products, and in fiscal 2025 it kept generating commercial revenue from approved hATTR amyloidosis use. Product sales remain the core revenue base, with ONPATTRO supporting recurring cash flow from an established, reimbursed therapy.
Product sales GIVLAARI
GIVLAARI adds revenue from acute hepatic porphyria, a rare specialist market, and Alnylam Pharmaceuticals, Inc. reported $1.6 billion in total product revenues in 2024, with GIVLAARI helping widen the mix beyond larger rare-disease products. Its monthly dosing supports repeat sales in a small, clinic-led segment.
Product sales OXLUMO
OXLUMO generates revenue from sales to patients with primary hyperoxaluria type 1 (PH1), a very rare kidney disease affecting about 1 to 3 people per 1,000,000. As a marketed Alnylam Pharmaceuticals, Inc. product, it adds a distinct rare-disease stream and broadens the company’s commercial portfolio.
Collaboration and licensing income
Alnylam Pharmaceuticals, Inc. earns collaboration and licensing income from partnered RNAi programs, with cash coming from upfront fees, milestones, and development-related payments. In 2025, this revenue stream still supported a platform that had delivered 5 approved medicines by mid-2026, showing how external deals help fund pipeline work without relying only on product sales.
Upfront fees from partners
Milestones tied to progress
Development reimbursements and royalties
Royalties and future launches
Partnered, licensed programs can still pay Alnylam Pharmaceuticals, Inc. royalties, so upside is not limited to direct sales. With 4 marketed products in 2025 and more label expansions or new approvals possible, future launches can add revenue on top of the current portfolio.
- Royalties add low-cost upside.
- New approvals can lift sales.
Alnylam Revenue: Rare-Disease Sales Plus Partnership Income
Alnylam Pharmaceuticals, Inc. mainly earns from sales of ONPATTRO, GIVLAARI, OXLUMO, and AMVUTTRA, with 2025 product revenue led by AMVUTTRA and a total revenue base still anchored by rare-disease prescriptions. Collaboration and licensing income from RNAi partners adds upfront fees, milestones, development payments, and royalties, reducing reliance on direct sales alone.
| Revenue stream | 2025 role |
|---|---|
| Product sales | Main source |
| Partnership income | Upfronts, milestones, royalties |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.